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receptor (CAR) specific for the CD19 antigen (CD19.CAR-Ts)
is a very effective treatment in B cell lymphoid malignancies.
However, B cell aplasia and cytokine release syndrome (CRS)
secondary to the infusion of CD19.CAR-Ts remain significant
drawbacks. The inclusion of safety switches into the vector en-
coding the CAR is seen as the safest method to terminate the
effects of CD19.CAR-Ts in case of severe toxicities or after
achieving long-term sustained remissions. By contrast, the
complete elimination of CD19.CAR-Ts when CRS occurs
may jeopardize clinical responses as CRS and antitumor activ-
ity seem to concur. We have demonstrated, in a humanized
mouse model, that the inducible caspase-9 (iC9) safety switch
can eliminate CD19.CAR-Ts in a dose-dependent manner, al-
lowing either a selective containment of CD19.CAR-T expan-
sion in case of CRS or complete deletion on demand granting
normal B cell reconstitution.Received 2 August 2016; accepted 18 January 2017;
http://dx.doi.org/10.1016/j.ymthe.2017.01.011.
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The adoptive transfer of T cells expressing a chimeric antigen receptor
(CAR) specific for the CD19 antigen (CD19.CAR-Ts) promotes
potent clinical responses in patients affected by acute lymphoblastic
leukemia (ALL)1–3 and lymphomas.4 Effective antitumor activity is
achieved regardless of the co-stimulation (CD28 versus 4-1BB) pro-
vided to the CAR.2,3 Similarly, side effects of CD19.CAR-Ts encoding
either CD28 or 4-1BB, like cytokine release syndrome (CRS) and
neurological toxicities, are superimposable.2–4 Long-term B cell apla-
sia, the limiting “on target-off tumor” toxicity of CD19.CAR-Ts,
strongly correlates with their long-term survival.2
Controlling effectively CRS and long-term B cell aplasia, while main-
taining potent antitumor activity, are relevant aspects to address prior
to introducing CD19.CAR-Ts to the standard practice. The inclusion
of safety switches or suicide genes into the vector encoding the CAR is
largely seen as the most effective and precise approach to rapidly580 Molecular Therapy Vol. 25 No 3 March 2017 ª 2017 The American Seliminate CAR-Ts in case of toxicities without causing additional
side effects.5–9 The activation of currently available safety switches
produces significant or complete elimination of CAR-Ts and, if
included in CD19.CAR-Ts, would assist in terminating their effects
to allow the reconstitution of normal B lymphocytes in patients
who achieved sustained remission. By contrast, the control of CRS
adds complexity to most of the available suicide approaches, as they
function as “on-or-off” switches and do not allow any modulation.
Being CRS likely interconnected with antitumor effects, the ability
to control the symptoms associated with the life-threatening CRS
without extinguishing CD19.CAR-T function is required for sustain-
ing the ongoing antitumor activity.1,2
The inducible safety switch caspase-9 (iC9) is based on a modified
human caspase-9 fused to the human FK506 binding protein
(FKBP) to grant conditional dimerization using a chemical inducer
of dimerization (CID) (AP1903/Rimiducid, Bellicum Pharmaceu-
tical) with consequent apoptosis of cells expressing the fusion pro-
tein.10,11 This safety switch is extremely potent and specific in rapidly
eliminating >85%–90% of iC9-tranduced T cells after the administra-
tion of one single dose of AP1903.12–14 While so far clinically used as
all classic safety switches to terminate transduced T cells, iC9 is, how-
ever, capable of activating ex vivo apoptosis of targeted cells in a dose-
dependent fashion upon binding to the CID.11,15,16 Taking advantage
of this unique pharmacological modulation of the iC9-induced
apoptosis, we have constructed and validated in vivo in a humanized
mouse model a novel CD19.CAR incorporating the iC9 safety switch
(iC9.CD19.CAR-Ts) and showed that iC9 can not only aid in theociety of Gene and Cell Therapy.
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Figure 1. Generation of Activated T Lymphocytes that Co-express an Inducible Caspase-9, a CD19-Specific CAR, and a Truncated NGFR
(A) Retroviral constructs used to transduce activated T cells. (B) Flow cytometry plots for CAR and NGFR expression in control T cells (Ctr-Ts), CD19.CAR-Ts, and
iC9.CD19.CAR-Ts in a representative experiment (upper panels) and summary of T cell lines generated from six healthy individuals (lower panels). (C) Fold expansion of
Ctr-Ts, CD19.CAR-Ts, and iC9.CD19.CAR-Ts. Data are means ± SEM of T cell lines generated from six healthy individuals. (D) T cell counts of iC9.CD19.CAR-Ts selected
using the indicated different concentration of NGFR Ab/107 cells and expanded ex vivo. Data are means ± SEM of T cell lines generated from six healthy individuals. (E) Mean
fluorescence intensity (MFI) of CAR and NGFR of T cells selected with the indicated amount of NGFR-PE Ab/107 cells. Data shown are means ± SEM of T cell lines generated
from nine healthy individuals.
www.moleculartherapy.orgon-demand ablation of iC9.CD19.CAR-Ts to allow B cell reconstitu-
tion, but also contains the expansion of iC9.CD19.CAR-Ts in case of
CRS, without complete elimination of these cells for sustained anti-
tumor activity.
RESULTS
Incorporation of a Truncated Form of the Low-Affinity Nerve
Growth Factor Receptor Allows Reproducible Selection of
iC9.CD19.CAR-Ts
We have previously validated the use of a truncated CD19 molecule
in combination with the caspase-9 safety switch as a marker/selection
gene both in vitro and in vivo in patients.12,17 We chose to incorpo-
rate in the CAR a truncated NGFR as a marker/selection gene, based
on its previous clinical validation in combination with the HSVTK
suicide system and thus availability of clinical grade selection re-
agents.18,19 Activated T cells from six healthy donors were transduced
with either Ctr or CD19.CAR or iC9.CD19.CAR vectors (Figure 1A)
and CAR expression, assessed 3–4 days after viral transduction, was
77% ± 4% and 61% ± 5%, respectively (Figure 1B). Nerve growth fac-
tor receptor (NGFR) expression by iC9.CD19.CAR-Ts was similar to
CAR expression (60% ± 4%, p = 0.6). The expansion rate of both
CD19.CAR-Ts and iC9.CD19.CAR-Ts was comparable (Figure 1C).To select iC9.CD19.CAR-Ts, we performed a titration of the primary
NGFR-PE antibody (Ab). Specifically, 5 days after transduction,
iC9.CD19.CAR-Ts were incubated with increasing concentration of
the primary NGFR-PE Ab, ranging from 1 to 10 mL/107 cells. After
immunomagnetic selection, iC9.CD19.CAR-Ts were expanded
ex vivo in interleukin-7 (IL-7) and IL-15 cytokines for a total of
18 days. We found that T cell recovery was significantly reduced
when lower doses (1 and 3 mL/107 cells) of NGFR-PE Ab were
used, as compared to higher doses (6 and 10 mL/107 cells;
p < 0.05). However, after selection, iC9.CD19.CAR-Ts expanded
equally well, regardless of the amount of NGFR-PE Ab used (Fig-
ure 1D). More than 90% of selected iC9.CD19.CAR-Ts expressed
both NGFR and CAR, irrespective of the dose of NGFR-PE
Ab used, but, as expected, the MFI of the NGFR was higher
in iC9.CD19.CAR-Ts selected with lowest dose of the antibody
(p = 0.04) (Figure 1E).
iC9.CD19.CAR-Ts Are Functional In Vitro
We characterized CD19.CAR-Ts and selected iC9.CD19.CAR-Ts to
ensure their comparable functions. We found no significant differ-
ences in cell memory composition (Figure 2A) or CD4 versus CD8
ratio (data not shown). Similarly, their cytotoxic activity against theMolecular Therapy Vol. 25 No 3 March 2017 581
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Figure 2. Functionality In Vitro of iC9.CD19.CAR-Ts
(A) Immunophenotypic analyses of Ctr-Ts, CD19.CAR-Ts, and iC9.CD19.CAR-Ts for one representative donor. The analysis was performed gating on CAR-expressing cells,
except for Ctr-Ts. (B) Cytotoxic activity of Ctr-Ts, CD19.CAR-Ts, and iC9.CD19.CAR-Ts selected using the indicated concentration of the NGFR-PE Ab/107 cells. Left and
right graphs show the percentage of lysis of the CD19+ Raji and the CD19– K562 cell lines, respectively, in a 51Cr-based release assay. (C) Percentage of tumor cells in
experiments in which CD19+ Raji cells were co-cultured at 1:1 ratio with Ctr-Ts, CD19.CAR-Ts, or iC9.CD19.CAR-Ts selected using the indicated concentration of NGFR-PE
Ab/107 cells. T cells and tumor cells were quantified by flow cytometry. (D) Quantification of IFN-g and IL-2 released in the supernatant by Ctr-Ts, CD19.CAR-Ts, or
iC9.CD19.CAR-Ts co-cultured for 24 hr with CD19+ Raji cells at 1:1 ratio and quantified by Milliplex assay. (E) Percentage of proliferation by Ctr-Ts, CD19.CAR-Ts, and
iC9.CD19.CAR-Ts in response to CD19+ Raji cells (ratio 1:1). iC9.CD19.CAR-Ts were selected using the indicated concentration of the NGFR-PE Ab/107 cells, and T cell
proliferation was measured using the CFSE staining. (F) Percentage of viable Ctr-Ts, CD19.CAR-Ts, and iC9.CD19.CAR-Ts after incubation with 10 nM of CID.
iC9.CD19.CAR-Ts were selected using the indicated concentration of NGFR-PE Ab/107 cells and alive cells quantified using the Annexin-V/7-AAD staining. Shown data are
means ± SEM of T cell lines generated from six healthy individuals.
Molecular TherapyCD19+ Raji tumor cells was comparable irrespective of the amount of
NGFR-PE Ab used for the selection (Figure 2B), with minimal activ-
ity against the CD19– K562 cells (Figure 2B). Long-term co-culture
assays of CD19.CAR-Ts and iC9.CD19.CAR-Ts confirmed compara-
ble antitumor activity, with complete elimination of CD19+ Raji tu-
mor cells by day 5 of co-culture (Figures 2C and S1A). From the
same co-cultures, cytokines were measured in supernatant collected
after 24 hr incubation, and no differences in IL-2 or interferon
(IFN)-g release were observed (Figures 2D and S1B). Of note, no
specific release of IL-6 was found by CAR-Ts in response to the spe-582 Molecular Therapy Vol. 25 No 3 March 2017cific antigen (Figure S1B), suggesting, as previously described,20 that,
in patients experiencing CRS, IL-6 is unlikely produced by CAR-Ts.
Similarly, CD19.CAR-Ts and iC9.CD19.CAR-Ts showed compara-
ble proliferative capacity in response to CD19+ Raji cells (Figures
2E and S1C), confirming that the inclusion of the iC9 does not
adversely affect CAR-T characteristics. Finally, we tested the func-
tion of the iC9 component by incubating iC9.CD19.CAR-Ts with
10 nM of CID. Less than 10% viable cells were detected after
24 hr incubation, irrespective of the dose of NGFR-PE Ab used (Fig-
ures 2F and S1D).
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Figure 3. In Vivo Expansion of iC9.CD19.CAR-Ts and Effects of CID
NSG mice were engrafted with CD34+ cells isolated from umbilical cord blood units and, upon engraftment of human hematopoietic cells, infused with Ctr-Ts or
iC9.CD19.CAR-Ts labeled with eGFP-FFluc. (A) Summary of bioluminescence signals (BLI, total plux) of Ctr-Ts (13 mice) and iC9.CD19.CAR-Ts treated with either vehicle
(16 mice) or CID (50 mg/mouse) (8 mice) by day 6. Lines are average (±SEM) of the bioluminescence intensity for each group. (B) Images from representative mice before and
after receiving either vehicle or CID. (C) Percentage of circulating CD19+ (gray bars) and CD3+ (white bars) cells (gated on human CD45+ cells) in mice before and after
receiving Ctr-Ts or iC9.CD19.CAR-T cells. (D) Percentage of circulating CD19+ (gray bars) and CAR+ (black bars) cells (gated on human CD45+ cells) in mice before (Pre-Ts)
and after (Post-Ts) iC9.CD19.CAR-Ts infusion. Shown are also data before and after (7 or >30 days) treatment with vehicle or CID (50 mg/mouse). Bars are means ±SEM of at
least ten mice/group. (E) IFN-g, TNF-a, and IL-6 measured in the plasma of mice treated as per (C and D). Bars are means ± SEM.
www.moleculartherapy.orgiC9.CD19.CAR-Ts Proliferate In Vivo in a Humanized Mouse
Model but Are Efficiently Eliminated by CID, Allowing B Cell
Reconstitution
To validate in vivo the activity of iC9.CD19.CAR-Ts, we used a
humanized mouse model generated by engrafting CD34+ cells in
sub-lethally irradiated NSG mice.21 Upon confirmed engraftment of
humanCD45+ cells,mice received eitherCtr-Ts or iC9.CD19.CAR-Ts,
labeled with eGFP-FFLuc (Figure S2A). T cell expansion was moni-
tored by bioluminescence intensity (BLI). Since the purpose of these
experiments was to assess primarily the capacity of iC9 to control
the toxic effects of iC9.CD19.CAR-Ts associated with CRS, we used
allogeneic Ctr-Ts and iC9.CD19.CAR-Ts to maximize their in vivo
expansion in response to the CD19 antigen expressed by B lympho-
cytes. For these experiments, we used iC9.CD19.CAR-Ts selected
with 3 mL/107 cells of NGFR-PE Ab, which warranted acceptableT cell recovery and adequate response to CID. Our data were also
confirmed in additional experiments with mice infused with Ctr-Ts
and iC9.CD19.CAR-Ts not labeled with eGFP-FFLuc. Starting from
day 2 post-infusion, iC9.CD19.CAR-Ts expanded rapidly and at
significantly higher level as compared to Ctr-Ts (Figure 3A) or to
iC9.CD19.CAR-Ts infused in non-humanizedNSGmice (Figure S3B),
confirming that the increase/expansion of iC9.CD19.CAR-Ts is pre-
dominantly mediated by the engagement of the CD19 expressed by
B cells. The BLI increase was paralleled by a greater increment of circu-
lating CD3+ (and CAR+) cells in mice infused with iC9.CD19.CAR-Ts
(84% ± 2%) as compared to mice infused with Ctr-Ts (54% ± 7.5%;
p = 0.003) (Figure 3C). Mice infused with iC9.CD19.CAR-Ts labeled
with eGFP-FFluc were treated by day 7 post-T cell infusion, when
the BLI usually reached the highest values, with either AP20187
(CID 50 mg/mouse) or AP20178 diluent (vehicle). BLI rapidlyMolecular Therapy Vol. 25 No 3 March 2017 583
Molecular Therapydecreased only in mice receiving CID and remained low over the
following observation period (p < 0.001; Figures 3A and 3B). This
was paralleled by the disappearance of iC9.CD19.CAR-Ts only in
mice treated with CID (2.2% ± 0.6% versus 77% ± 6.5%; p < 0.001)
(Figure 3D). All mice receiving Ctr-Ts maintained circulating
CD19+B lymphocytes (38.8%± 7.1%of theCD45+ human cells), while
mice infused with iC9.CD19.CAR-Ts almost completely cleared
B lymphocytes post-T cell infusion (2% ± 1.3%; p < 0.001 by day
7 post-T cells) (Figure 3C). CD19+ B cells started to recover in periph-
eral bloodonly inmice treatedwithCID (6.5%± 3.7%, p =0.4) (Figures
3D and S2C). B cell reconstitution and lack of iC9.CD19.CAR-Ts were
observed long term in mice treated with CID (28.8% ± 6%; p = 0.02%
and 2.9% ± 1.3%; p < 0.001%, respectively), while B cell aplasia and
iC9.CD19.CAR-Ts persisted in mice that received vehicle (Figures
3D and S2D). When we analyzed the health conditions of the mice,
we found that five of the 13 (38%)mice infused with Ctr-Ts developed
signs consistent with xenograft versus host disease (GVHD), including
fur and weight loss (18 ± 0.6 gr) and hunched posture, and these mice
required euthanizationwithin 30 days after T cell infusion. In contrast,
none of the mice treated with iC9.CD19.CAR-Ts experienced signifi-
cant loss weight (21 ± 0.5 gr, p = 0.031). Interestingly, mice receiving
iC9.CD19. CAR-Ts experienced a transient weight loss (compared to
pre CAR-T weight of 22.6 ± 0.4 gr, p = 0.028) and agitation within
10 days from T cell infusion. Although we did not monitore fever or
blood pressure (all signs associated with CRS in humans),22 we
measured higher level of human cytokines like IFN-g, IL-6, and tumor
necrosis factor alpha (TNF-a) (Figure 3E) in the plasmaofmice treated
with iC9.CD19.CAR-Ts (compared to those treated with Ctr-Ts),
which resemble the profile of cytokines released in sera of patients
treated with CD19.CAR-Ts experiencing CRS.2,23 Importantly, we
observed that IL-6 (111 ± 27 pg/mL) decreased in mice treated with
iC9.CD19.CAR-Ts once they received CID (to 15 ± 6 pg/mL; p <
0.05) but increased inmice receiving vehicle (to 245 ± 143 pg/mL; Fig-
ure 3E). Overall, only three of the 16 mice (19%) treated with
iC9.CD19.CAR-Ts and receiving vehicle died of indeterminate causes
(pathology was not available to distinguish between either GVHD or
sustained pro-inflammatory conditions induced by the continuous
expansion of iC9.CD19.CAR-Ts), while all mice treated withCID fully
recovered including their bodyweight (21.7± 0.5 gr; p = not significant
[NS]).
iC9.CD19.CAR-Ts Have Antitumor Activity In Vivo
Having shown that iC9.CD19.CAR-Ts deplete normal B lymphocytes
in our humanizedmice, we used thismodel to test CD19.CAR-Ts anti-
tumor activity. Humanized mice, upon confirmed engraftment of
CD45+ cells, received FFluc-labeled Daudi cells, and, 3 days later,
Ctr-Ts or iC9.CD19.CAR-Ts.5When tumor growthwas clearly detect-
able by an in vivo imaging system (IVIS) in the Ctr-Ts group, mice
infused with iC9.CD19.CAR-Ts were randomized for vehicle or CID
(50 mg/mouse) administration (Figure 4). While tumor-BLI rapidly
increased in mice treated with Ctr-Ts, tumor signals remained low
in mice infused with iC9.CD19.CAR-Ts regardless of whether they
received vehicle or CID (Figure 4A). Normal B cells rapidly disap-
peared from the circulation after the infusion of iC9.CD19.CAR-Ts.584 Molecular Therapy Vol. 25 No 3 March 2017CD19+ B cells with l- and k-light restricted chains reconstituted in
mice receiving CID, while remaining undetectable in mice infused
with vehicle (Figure 4B).Mice infusedwith iC9.CD19.CAR-Ts showed
no significant differences in tumor-free survival when treated with
vehicle or CID. By day 80 post-infusion, tumor had developed in three
of 24 (13%) mice receiving vehicle and in four of 18 mice (22%)
receiving CID (Figure 4C). Late tumor recurrence especially in the
CNS was observed, which is consistent with our previous results in
non-humanized mouse models (data not shown).
The Pro-apoptotic Function of the iC9 CanBeModulated In Vitro
T cells expressing iC9 display in vitro a CID dose-response induction of
apoptosis.11,17 Similarly iC9.CD19.CAR-Ts retained a titratable induc-
tion of apoptosis in response to CID in vitro (Figure 5A). To demon-
strate that the expression levels of iC9 are critical in defining the fraction
of cells spared by exposure to low doses of CID, positively selected
iC9.CD19.CAR-Tswere expanded ex vivo and then further flow-sorted
in NGFRlow and NGFRhigh-expressing cells (Figure 5B). Sorted cells
were then exposed to either 0.1 or 10 nM of CID. NGFRhigh cells
were consistently <10% viable when incubated with either 0.1 or
10 nM of CID, while NGFRlow cells were significantly spared when
exposed to 0.1 nM of CID (p < 0.05; Figure 5C). We also found that
the prominent dose effect of the CID in NGFRlow cells was due to their
activation status. Upon T cell receptor (TCR) activation, NGFRlow cells
showed similar susceptibility to apoptosiswhenexposed to0.1 or 10nM
of CID (6.1% ± 3% versus 11.4% ± 3.5% viable cells) (Figures 5C and
S3A) and increased transcription of the iC9 transgene, since the copies
of iC9 per integration reached values equivalent to those of non-acti-
vated NGFRhigh cells (Figure 5D). Importantly, we confirmed that
iC9.CD19.CAR-Ts spared after incubation with 0.1 nM of CID re-
tained functional expression of the CAR (Figure S3B), as indicated
by their capacity to lyse CD19+ tumor cells in short term (Figures
5E and 5F) and long-term killing assays (Figure S3E). We have also
performed immunophenotypic analyses to determine memory and
exhaustion markers in T cells spared after exposure to low doses of
CID. Overall, the only significant difference was observed in the fre-
quency of Tim3+ cells (from 58% ± 9.5% to 25% ± 3.4%, p =
0.0053), but not in other exhaustion markers like PD1 or CD57 (Fig-
ures S3C and S3D).We observed a slight but not significant reduction
in CD8+, CD45RA+CCR7+, and CD27+CD28+ cells (Figures S3C and
S3D), which express the CAR/NGFR molecules at modestly brighter
levels. Finally, iC9.CD19.CAR-Ts spared upon exposure to low doses
of CID were infused into tumor-bearing mice and showed retained
ability to control tumor growth (Figure S3F). Overall our data suggest
that the exposure of iC9.CD19.CAR-Ts to CID does not cause selec-
tion of CAR-Ts phenotypically distinct from those eliminated by
CID, and that CID-spared iC9.CD19.CAR-Ts maintain proliferative
capacity and antitumor activity.
The Viability of iC9.CD19.CAR-Ts Can Be Pharmacologically
Modulated In Vivo by Titrating theDose of theNGFR-PEAbUsed
for Selection and the Dose of the CID
We then determined whether the pro-apoptotic function of iC9 can
be modulated in vivo to contain the release of cytokines associated
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Figure 4. In Vivo Antitumor Activity of iC9.CD19.CAR-Ts
Upon engraftment of human hematopoietic cells, mice were infused with CD19+ Daudi cells labeled with eGFP-FFluc. Three days later, mice received Ctr-Ts or
iC9.CD19.CAR-Ts and 10 days later either vehicle or CID 50 mg/mouse. (A) Bioluminescence signals of the CD19+ FFluc-Daudi tumor cells. The left panel shows the mean
bioluminescence intensity (BLI) for each mouse/group, while the right panel illustrates images from three representative mice/group. (B) Immunophenotypic analyses of
peripheral blood samples of representative treated mice at the indicated time point. Light-chain immunoglobulin restriction was analyzed long term on mice reconstituting
normal CD19+ B lymphocytes. (C) Shown is the Kaplan-Meier survival curve.
www.moleculartherapy.orgwith CRS, without completely depleting iC9.CD19.CAR-Ts. We took
advantage of our humanized mouse model and compared in mice the
effects of iC9.CD19.CAR-Ts selected with stringent or less stringent
NGFR-PE Ab-selection conditions, and different doses of CID. In
the first set of experiments, eGFP-FFluc-labeled iC9.CD19.CAR-Ts
selected using stringent conditions (3 mL/107 cells of NGFR-PE Ab)
were infused in CD34+ engrafted mice. Mice were then randomized,
based on BLI, to receive either vehicle or decreasing doses of CID (50,
25, or 12.5 mg/mouse). While increasing in mice receiving vehicle, BLI
decreased >2 logs within 24 hr after CID administration (p < 0.02),
regardless of the dose (Figure 6A). Plasma levels of human
IFN-g, IL-6, and TNF-a were also equally reduced after CID admin-
istration, at all tested doses (Figure 6B). In sharp contrast, when
iC9.CD19.CAR-Ts were selected using less stringent conditions of
NGFR-PE Ab (6 mL/107 cells), we observed a CID dose-dependent
elimination of iC9.CD19.CAR-Ts in vivo. Indeed, in mice treated
with 12.5 mg/mouse of CID we discovered an inferior elimi-
nation of iC9.CD19.CAR-Ts compared to mice receiving higherCID doses (p < 0.02) (Figure 6C). Importantly, mice treated with
iC9.CD19.CAR-Ts selected with less stringent conditions, and
12.5 mg/mouse of CID continued to produce significant amount of
IFN-g, while circulating levels of IL-6 were equally reduced as in
mice treated with higher doses of CID (Figure 6D). In line with
the inferior elimination of iC9.CD19.CAR-Ts after administra-
tion of a low dose of CID, these mice had reduced CD19+ B cell
recovery (p < 0.05; Figure 6E) and higher number of circulating
iC9.CD19.CAR-Ts over time (p < 0.05; Figure 6F), as compared to
mice receiving iC9.CD19.CAR-Ts selected with stringent conditions,
where elimination of iC9.CD19.CAR-Ts allowed B cell recovery.
In selected experiments, Ctr-Ts or iC9.CD19.CAR-Ts were injected in
mice with high FFluc-tumor burden (day 7 or 14 post-tumor inocu-
lation). As observed in the experiments in which mice were treated in
condition of low tumor burden, iC9.CD19.CAR-Ts still appropriately
controlled tumor growth (Figures 7A and S4A). Mice were then
divided in two groups and received vehicle or CID (12.5 mg/mouse)Molecular Therapy Vol. 25 No 3 March 2017 585
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Figure 5. Modulation of iC9.CD19.CAR-T Function In Vitro by CID
(A) Number of viable iC9.CD19.CAR-Ts enumerated 24 hr after exposure to escalating doses of CID in vitro. Shown are mean ± SEM of T cell lines generated from seven
healthy individuals. The histogram on the right shows the levels of NGFR expression in cells detected 24 hr after the exposure to the indicated doses of CID. (B) Shown is the
cell-sorting gating strategy to isolate NGFRhigh and NGFRlow iC9.CD19.CAR-Ts in one representative donor. (C) Percentage of viable iC9.CD19.CAR-Ts in NGFRhigh and
NGFRlow-selected cells after the exposure to either 0.1 or 10 nM of CID and normalized to cells treated with vehicle. The experiment was repeated using iC9.CD19.CAR-Ts
non-activated or activated with CD3/CD28 mAbs. (D) Copies of iC9 transcripts/integration site in NGFRhigh and NGFRlow cells non-activated or activated with CD3/CD28
mAbs. (E) Cytotoxic activity of iC9.CD19.CAR-Ts non-exposed to CID or exposed to 0.1 nM of CID. The left and right graphs show the percentage of lysis of the CD19+ Raji
and the CD19– HDLM-2 tumor cell lines, respectively, in a 51Cr-based release assay. Ctr-Ts were used as control. (F) Shown is the histogram of NGFR andCAR expression of
the cells assayed for the cytotoxic activity in (E). Data are means ± SEM of T cell lines generated from four healthy individuals.
Molecular Therapy7–10 days post-T cell infusion as soon as the tumor BLI signal reached
background levels. As shown in Figure 7A, mice remained tumor free
by day 80 post-treatment. In parallel experiments, 5–10 days after the
administration of CID (12.5 mg/mouse), mice were re-challenged with
FFluc-tumor cells. Remarkably, iC9.CD19.CAR-Ts remaining after
the administration of low doses of CID controlled tumor growth, un-
like control mice (Figures 7B and S4B). This effect was clearly medi-
ated by iC9.CD19.CAR-Ts that, spared by the administration of a low
dose of CID, promptly re-expanded upon tumor re-challenge (Fig-
ure 7C). As shown in Figure 7D, tumor-free survival of mice treated
with iC9.CD19.CAR-Ts and a low dose of CID was similar to that of
mice receiving iC9.CD19.CAR-Ts and vehicle confirming the safety
and efficacy of our proposed strategy.586 Molecular Therapy Vol. 25 No 3 March 2017DISCUSSION
We have shown that the expansion of CD19.CAR-Ts can be tightly
modulated when the vector encoding the CAR contains the iC9 safety
switch and a selectable marker. The appropriate combination of strin-
gency for the in vitro selection of iC9.CD19.CAR-Ts and the low
doses of CID that activates the iC9 provides a specific containment
of iC9.CD19.CAR-T expansion and cytokine release, without abro-
gating their function. When required, a higher dose of the CID can
be used to completely eliminate iC9.CD19.CAR-Ts and promote
the reconstitution of normal B lymphocytes.
While the administration of CD19.CAR-Ts has reached excellent
response rates in B cell-derived malignancies, the associated toxicities
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Figure 6. Modulation of iC9.CD19.CAR-T Function In Vivo by CID
Mice were infused with eGFP-FFLUc-iC9.CD19.CAR-Ts and treated at the peak of expansion with either vehicle or different doses of CID (50, 25, and 12.5 mg/mouse). For
these experiments, iC9.CD19.CAR-Ts were selected using either 3 mL/107 cells (A and B) or 6 mL/107 cells (C and D) of the NGFR-PE Ab. (A) and (C) show bioluminescence
signals (BLI) of iC9.CD19.CAR-Ts in mice treated with either vehicle or the indicated doses of CID. Lines show themeans bioluminescence ± SEM for tenmice/group. (B) and
(D) show themeasurement of IFN-g, IL-6, and TNF-a in the plasma of mice treated with iC9.CD19.CAR-Ts and analyzed 7 days after they received either vehicle or CID. Bars
are means ± SEM of ten mice. (E) Percentage of circulating B cells in mice treated with iC9.CD19.CAR-Ts (selected with 3 mL/107 cells or 6 mL/107 cells of NGFR Ab) at days
35–40 after infusion of vehicle or CID. Bars are means ± SEM of ten mice. (F) Percentage of circulating iC9.CD19.CAR-Ts (selected with 3 mL/107 cells or 6 mL/107 cells of
NGFR Ab) at days 35–40 after infusion of vehicle or CID. Bars are means ± SEM of ten mice.
www.moleculartherapy.orgrequire further refinement for this strategy. B cell aplasia is an indica-
tor of CD19.CAR-T persistence and function.2 Given that the number
of patients infused with CD19.CAR-Ts is rapidly increasing, it will be
soon possible to correlate sustained clinical responses with the dura-
tion of the B cell aplasia and likely define a therapeutic window in
which it is reasonably safe to terminate the effects of CD19.CAR-Ts
without causing tumor relapse. Thus, on-demand blunting of
CD19.CAR-Ts to revert an undesired and unnecessary long-term
B cell aplasia is a critical requirement. While T lymphocytes can be
eliminated by lymphodepleting chemotherapy, antibodies, or high-
dose steroids, the incorporation of a safety switch within CAR-Ts rep-
resents a more precise and selective approach. Safety switches
encoded in combination with CARs include the iC9, herpes simplex
thymidine kinase (HSV-TK), epidermal growth factor receptor
(EGFR), and CD20, which induce T cell death upon exposure to
CID, ganciclovir, cetuximab, and rituximab, respectively.5,7,8,25,26
All these safety switches seem equally effective in eliminating the
transduced T cells, but only iC9, and HSV-TK have been extensivelytested clinically, in the context of the donor leucocyte infusion after
haploidentical stem cell transplant.12–14,27,28 Of these two options,
iC9 may have a superior clinical profile, when taking into account
the selectivity and rapidity of T cell elimination and the low level of
immunogenicity.29
The iC9 has been used in the past to efficiently eliminate CAR-Ts
preclinically in the context of immuno-deficient mice, but its
function and specifically its tuning properties have never been
tested in a humanized mouse model. We have demonstrated here
that when the iC9 safety switch is combined with the CD19.CAR,
iC9.CD19.CAR-Ts can be efficiently eliminated by the administration
of CID, allowing the reconstitution of normal B lymphocytes. In addi-
tion, although with the limits of a mouse model, we show that the
ablation of iC9.CD19.CAR-Ts after the elimination of the tumor cells
does not necessarily cause tumor relapse. Although it has been re-
ported that adoptive transfer of human T or CAR-Ts in NSG mice
can lead to the development of xeno-GVHD30 and a fraction of ourMolecular Therapy Vol. 25 No 3 March 2017 587
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Figure 7. Modulation of iC9.CD19.CAR-T Function In Vivo in High Tumor Burden and Re-challenge Tumor Models
FFLUc-tumor engrafted mice received Ctr-Ts or iC9.CD19.CAR-Ts on days 14 (A) or 10 (B) (ten mice/group). (A) Upon decrease of tumor bioluminescence signals after
iC9.CD19.CAR-T treatment, mice were randomized to receive either vehicle or CID (12.5 mg/mouse) and monitored over time for tumor growth. (B) In selected experiments,
5 days post-vehicle or CID treatment (12.5 mg/mouse), mice were re-challenged with the same dose of FFluc-CD19+ tumor cells and monitored over time for tumor growth.
(C) Immunophenotypic analyses of peripheral blood samples of representative mice treated according to the schedule described in (B). (D) Kaplan-Meier survival curve of
combined experiments in (A) and (B). Data are means ± SEM of ten mice.
Molecular Therapycontrol mice develop symptoms compatible with GVHD, our data
suggest that the CAR-driven effect (B cell aplasia and antitumor activ-
ity) can be differentiated from any potential allogeneic/xenogeneic ef-
fects, as no apparent symptoms compatible with GVHD occurred in
our CAR-Ts-treated mice, while no B cell aplasia or control of tumor
growth occurred in control mice. Our observed results are not sur-
prising as, in a previously reported immunocompetent murine model,
GVHD occurring in mice receiving allogeneic CD19.CAR-Ts was
mediated exclusively by CD4+ CAR-Ts and importantly only when
CAR-Ts were given 2 days after bonemarrow transplant conditioning
therapy.24 Our model has no conditioning that would exacerbate
GVHD and is also in line with the robust clinical evidences from
National Cancer Institute in which donor-derived CD19.CAR-Ts
infused in the context of allogeneic stem cell transplant (without prior
chemotherapy or conditioning, as in our model) do not cause GVHD,
suggesting that the CAR-mediated signaling may overcome the
TCR-mediated signaling.31
The control of the CRS, which is another critical side effect of
CD19.CAR-Ts, is matter of intense investigation. CRS development588 Molecular Therapy Vol. 25 No 3 March 2017correlates with the expansion of CD19.CAR-Ts and its clinical
manifestations are largely associated with high plasma levels of
IL-6.1,2,22,23 The administration of Tocilizumab, which blocks the
IL-6 receptor and effectively controls the clinical manifestations of
CRS, and algorithms have been developed in the attempt to define
the optimal time for the administration of Tocilizumab to control
life-threatening CRS, without dramatically diminishing the antitumor
effects of CD19.CAR-Ts.2,22,23 However, a more precise control of
CD19.CAR-T expansion seems desirable. Elegant approaches have
been proposed to regulate the expansion of CAR-Ts by pharmacolog-
ically controlling T cell co-stimulation.32 Here, we suggest that the
iC9 safety switch not only can be used to terminate the effects of
iC9.CD19.CAR-Ts, but also can modulate their apoptotic rate, thus
controlling their expansion and the concomitant cytokine load.
The humanized mouse model we propose seems to mirror the role of
IL-6 as a player in the CRS clinical picture. Recent evidences point out
at IL-6 being produced by myeloid cells in response to the activated
T cells,24 and, while the mechanism is still under investigation, our
model for the first time attempts to recapitulate these events. In this
www.moleculartherapy.orgmodel, we show indeed that the iC9 safety switch has the unique
property to tune the expansion of iC9.CD19.CAR-Ts and reduce
the levels of circulating IL-6 when low doses of CID are used. None-
theless, iC9.CD19.CAR-Ts spared by low doses of CID remain effec-
tive in controlling tumor growth.
Experiments in vitro showed that 10–20 nM of CID are generally suf-
ficient in inducing >90% apoptosis of iC9-engineered T cells.11 The
administration of 0.4 mg/kg of CID causes over 85%–90% elimination
of iC9-engineered T cells in vivo.12,14 Of note, iC9-engineered T cells
not responding to the CID in vivo are not intrinsically resistant to the
drug but rather show either lower copy numbers of the transgene, or
relatively low transcriptional activity, resulting in lower iC9 protein
expression and thus reduced susceptibility to apoptosis CID medi-
ated.33 Taking advantage of this observation, we now proved that,
while high doses of CID removemost of the iC9.CD19.CAR-Ts, lower
doses preferentially eliminate iC9.CD19.CAR-Ts characterized by
either multiple copies of the transgene or higher transcriptional activ-
ity, sparing cells with lower copy numbers or low transcriptional ac-
tivity. We confirmed that the iC9.CD19.CAR-Ts spared by low doses
of CID retain CD19.CAR functionality in vitro and can be effectively
eliminated upon activation that mediates increased transcriptional
activity. More importantly, we demonstrated in the humanized
mouse model that low doses of CID calibrate the expansion of
iC9.CD19.CAR-Ts at sufficient levels to control plasma levels of
IL-6, while maintaining tumor control and protecting from tumor
re-challenge. Of note, we also showed that the inclusion of the trun-
cated form of the NGFR receptor as a selectable marker plays a deci-
sive role. Taking in consideration the variability in transduction
efficiency of iC9.CD19.CAR-Ts and the threshold levels of iC9
expression in causing T cell apoptosis after exposure to CID, the se-
lection of transduced cells based on the expression of the truncated
form of NGFR ensures a more consistent and predictable pattern of
transgene expression.
In summary, we showed that the iC9 safety switch incorporated
within the CD19.CAR provides the opportunity for balancing expan-
sion/toxicity and persistence/protection of CD19.CAR-Ts ensuring
their modulation in case of toxicities, like CRS, or their complete abla-
tion to restore B cell immunity. Although, the dimerizer drug is not
licensed for clinical indication, we are implementing a phase I clinical
study in collaboration with Bellicum Pharmaceutical aimed at identi-
fying the lowest dose of AP1903 allowing control of severe CRS
without ablating iC9.CD19.CAR-Ts to validate our observations in
patients.
MATERIALS AND METHODS
Cell Lines
293T cells, Daudi and Raji (CD19+ Burkitt lymphoma cell lines),
K562, and HDLM-2 (CD19– tumor cell lines) were purchased from
the American Type Culture Collection (ATCC) or the German
Collection of Microorganisms and Cell Cultures GmbH (DSMZ)
and maintained in culture with RPMI-1640 (Gibco-BRL) supple-
mented with 10% fetal bovine serum (FBS-HyClone, GE Healthcare)and 2 mM GlutaMAX (Gibco-BRL) in a humidified atmosphere con-
taining 5% CO2 at 37C. In selected in vivo experiments, Daudi cells
were transduced with a retroviral vector encoding the Firefly-Lucif-
erase gene (FFLuc).34 Cell lines were authenticated by the University
of Texas MD Anderson Cancer Center Characterized Cell Line Core
Facility (Houston, TX). All lines were routinely checked over the
course of the experiments and always found mycoplasma free and
routinely validated by flow cytometry for surface markers and func-
tional readouts as needed.
Generation of Retroviral Supernatant
We generated two retroviral vectors using the SFG backbone encod-
ing either CD19-specific CAR alone (CD19.CAR)35 or three genes
(iC9,11 a truncated form of the human low-affinity nerve growth fac-
tor receptor, DNGFR,19 and the CD19.CAR)35 (iC9.CD19.CAR)
linked by two 2A-like sequences (Figure 1A).5,36 The CD19.CAR
contains the 4-1BB co-stimulatory endodomain.37 For T cells, we
generated a retroviral vector encoding the eGFP-Firefly-Luciferase
(eGFP-FFluc) gene.36 The cassettes cloned into the vectors were
sequenced. Transient retroviral supernatants were produced by trans-
fection of 293T cells with the RD114 envelope (RDF plasmid), the
MoMLV gag-pol (PegPam3-e plasmid), and the retroviral vector.34
T Cell Transduction and Expansion
Buffy coats from healthy donors were obtained through the Gulf
Coast Regional Blood Center, Houston, TX. Peripheral blood mono-
nuclear cells (PBMCs), isolated with Ficoll-Paque (Amersham Biosci-
ences, GE Healthcare), were activated using immobilized OKT3 or
anti-CD3 (Miltenyi Biotec) and CD28 (BD Biosciences) antibodies
(Abs). On day 3, cells were transduced with retroviral supernatants
and expanded in complete medium (45%RPMI-1640 and 45%Click’s
medium [Irvine Scientific], 10% FBS, and 2mMGlutaMAX) and with
interleukin-7 (IL-7) (10 ng/mL; PeproTech) and IL-15 (5 ng/mL;
PeproTech), every 2–3 days.38 On day 8, cells were positively selected
using the CD271 Microbeads Kit (Miltenyi Biotec) consisting of
NGFR-PE and anti-PE beads. After selection, cells were plated in
complete medium with IL-7 and IL-15 for up to 18 days.38,39 In
parallel, we expanded in IL-7 and IL-15 mock-transduced (empty
SFG) T cells (Ctr-Ts). In selected experiments, both Ctr-Ts and
iC9.CD19.CAR Ts were transduced with a retroviral vector encoding
eGFP-FFLuc the day after transduction with the first vector.5
Flow Cytometry
Monoclonal Abs for CD45, CD3, CD8, CD19, CD20, CD45RA,
CD45RO, CD28, CD95, CD62L, CD14, CD33, k/l-light chains, and
CD271 (BD Biosciences) and CCR7 (R&D Systems) were used.
Expression of the CD19.CAR was detected using a specific anti-idio-
type scFv monoclonal antibody (mAb) (kindly provided by Dr. Law-
rence Cooper, MD Anderson Cancer Center).40 Cells were collected
using a BD-FACSCalibur, a five-laser BD-Fortessa, or the Gallios
Flow Cytometer (Beckman Coulter) and analyzed using FlowJo soft-
ware v.9.3 (Tree Star) or Kalusa software. In selected experiments,
counting beads (CountBright, Invitrogen) were added following
manufacturer’s instruction.Molecular Therapy Vol. 25 No 3 March 2017 589
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The cytotoxic activity of T cells against CD19+ and CD19– tumor cells
was determined using a standard 4-hr 51Cr-release assay at different
effector-to-target ratios (E:T; 40:1, 20:1, 10:1, and 5:1) and using a
gcounter (Perkin-Elmer).34
Long-Term Cytotoxic Activity
Tumor cells were seeded in 24-well plates at a concentration of
5  104/well. T cells were added to the culture at different ratios
(E:T of 5:1; 1:1, or 1:3) without cytokines. Supernatant was collected
after 24 hr to measure cytokine release and cells analyzed by day 5 to
measure residual tumor cells and T cells by fluorescence-activated cell
sorting (FACS) analysis based on CD20 and CD3 expression,
respectively.5,34
Proliferation Assay
T cells were labeled with 1.5 mmol/L carboxyfluorescein diacetate
succinimidyl ester (CFSE; Invitrogen) and plated with irradiated tu-
mor targets at an E:T ratio of 1:1. CFSE dilution was measured on
CD3+ cells by flow cytometry.5
Activation of the Safety Switch
The B/B homodimerizer AP20187, a caspase inducible drug (CID)
(Clontech Laboratories), was added at various concentrations to
T cell cultures and induction of apoptosis evaluated 24 hr later using
Annexin-V/7-AAD staining (BD Biosciences) and FACS analysis. In
selected experiments, AP20187 was added to cells (non-activated or
24 hr after activation with immobilized CD3 and CD28 mAbs) for
3–4 hr. Cells were subsequently washed, re-plated to mimic the rapid
clearance of the drug after in vivo administration,12,41 and then
counted based on viability using CountBright beads, to assess residual
cytotoxic activity and NGFR expression. Extensive immune-pheno-
typic analyses were also performed, using the same panel of anti-
bodies described in the flow cytometry section.
Sorting of NGFRhigh versus NGFRlow T Cells
In five donors, iC9.CD19.CAR-Ts were labeled with NGFR-PE and
sorted in NGFRlow (MFI mean: 494 ± 31) versus NGFRhigh (MFI
mean: 9,097 ± 1,085)-expressing cells using the Flow Sorting Core at
the University of North Carolina (Chapel Hill, NC). Sorted cells
were tested to determine the expression of iC9per integration copies.33
Measurement of Cytokines
Supernatants from T cell cultures and plasma from mice were
analyzed for cytokines using the Th17-specific Milliplex assay kit
(Millipore) following manufacturer’s instructions. Data were
analyzed using the Lumina-200 System and analyzed using the Milli-
plex Analyst 5.1 software (Millipore).
Humanized Mouse Models to Assess Expansion and Antitumor
Activity of T Cells
De-identified umbilical cord blood units (UCBs) were obtained
through the MD Anderson Cord Blood Bank (University of Texas,
Houston, TX) on a Baylor College ofMedicine (BCM) institutional re-590 Molecular Therapy Vol. 25 No 3 March 2017view board (IRB)-approved protocol or from the Carolinas Cord
Blood Bank (Duke Translational Research Institute, Durham, NC)
on a UNC-IRB-approved protocol. CD34+ cells were isolated using
immunomagnetic beads (Miltenyi) according to manufacturer’s in-
structions. In vivo experiments were performed according to BCM’s
Animal Husbandry guidelines on a BCM institutional animal care
and use committee (IACUC)-approved protocol and according to
UNC’s Animal Husbandry guidelines on a UNC-IACUC approved
protocol. Four-week-old female NSG mice (Jackson Laboratory and
UNC Animal Studies Core Facility) received intravenously (i.v.)
2  105 CD34+ cells after sub-lethal irradiation (250 rad). After
4–6 weeks, mice were analyzed for the engraftment of human-derived
CD45+ cells, including lymphocytes and myeloid cells21 and then
infused with either 5  106 Ctr-Ts or iC9.CD19.CAR-Ts, labeled
with FFluc to monitor proliferation and persistence using the Xeno-
gen-IVIS Imaging System (Caliper Life Sciences).5 To assess the func-
tion of the iC9,micewere infused intraperitoneally (i.p.) with different
doses of AP20187. T cell bioluminescent signal intensity (BLI) was
measured as total photon/s/cm2/sr (p/s/cm2/sr).5,36 To assess func-
tional activity of T cells, mice were bled at specific intervals
(10–15 days, as per BCM- and UNC-IACUC guidelines) to assess
plasma cytokines and frequency of CD19+ and CD3+ cells. The per-
centage of positive cells was calculated based on human CD45+-gated
cells. To assess antitumor activity, mice received 2 106 FFluc-labeled
Daudi cells5 and either Ctr-Ts or iC9.CD19.CAR-Ts or in selected ex-
periments ex vivo-CID pretreated iC9.CD19.CAR-Ts. Tumor growth
was measured by Xenogen-IVIS Imaging System. Mice were followed
for up to 90 days. Blood, spleen, bone marrow, and spinal cord cells
were collected and analyzed to detect the presence of human
CD45+, CD19+, andCD3+ cells and iC9.CD19.CAR-Ts. In selected ex-
periments, mice received T cells only when BLI signal indicated high
tumor burden. As soon as BLI declined indicating tumor elimination,
mice were randomized to receive vehicle or CID (12.5 mg/mouse) and
then monitored for tumor recurrence. In selected experiments, 7 days
after CID treatment, mice were re-challenged i.v. with 2 106 FFluc-
labeled Daudi cells and then monitored for tumor growth.
Statistical Analysis
All in vitro data are presented as average ± SEM. The statistical sig-
nificance of results with multiple comparisons was evaluated by
repeated-measures ANOVA. Student’s t test was used to determine
the statistical significance of differences between samples, and
p < 0.05 was accepted as indicating a significant difference. For
the BLI experiments, intensity signals were summarized using
average ± SEM at baseline and multiple subsequent time points for
each group of mice. Changes in intensity of signal from baseline at
each time point were calculated and compared using paired t tests
or Wilcoxon signed-rank test. Survival curves were generated by
GraphPad Prism v.5.0 for Mac (GraphPad).
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